Vitamin D3 metabolite injections to thyroparathyroidectomized pregnant rats: effects on calcium-binding proteins of maternal duodenum and of fetoplacental unit.
Fetomaternal relationships with respect to vitamin D metabolism were investigated in thyroparathyroidectomized (TPTX) pregnant rats, with or without treatment with different vitamin D3 metabolites. Calcium-binding protein (CaBP) in maternal duodenum was used as an index of 1,25-(OH)2D3 status of the mother. Pregnant rats were TPTX on day 12.5 and CaBP was measured on 21.5 days of gestation by RIA in maternal duodenal mucosa and in the fetoplacental unit (placenta, fetal membranes, and fetal intestine). In the duodenum of TPTX mothers, the CaBP concentration was reduced by 50%. This fall was associated with a decrease of 1,25-(OH)2D in maternal plasma. CaBP in maternal duodenum increased by the administration of 1,25-(OH)2D3 or 1,24,25-(OH)3D3. In contrast, 24,25-(OH)2D3 injections to TPTX mothers were ineffective. In both placenta and fetal membranes, CaBPs decreased by 20% in TPTX mothers and were normalized only in 1.25-(OH)2D3-treated TPTX mothers. In the fetal intestine, CaBP variations paralleled those of maternal duodenal CaBP. The data indicate that plasma levels of 1,25-(OH)2D in TPTX pregnant rats are partly under the control of maternal parathyroid glands, and they support that even in pregnancy, the CaBP concentration in maternal duodenum may well reflect the 1,25-(OH)2D status of the mother. The CaBP synthesis in placenta and fetal membranes are vitamin D-dependent, and their regulation differs from that of intestinal CaBP. It app]ears that 1 alpha-hydroxylase activities of the fetoplacental unit (placenta and fetal kidney) are blunted in TPTX animals and that CaBP synthesis in the fetus depends on the presence of 1 alpha-hydroxylated vitamin D3 metabolites in the mother.
D015650:24,25-Dihydroxyvitamin D 3; D000818:Animals; D002117:Calcitriol; D002118:Calcium / Q000097:blood; D002135:Calcium-Binding Proteins / Q000378:metabolism*; D002762:Cholecalciferol / Q000378:metabolism / Q000494:pharmacology*; D004100:Dihydroxycholecalciferols / Q000494:pharmacology; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D005333:Fetus / Q000187:drug effects / Q000378:metabolism*; D006887:Hydroxycholecalciferols / Q000494:pharmacology; D008431:Maternal-Fetal Exchange; D010280:Parathyroid Glands / Q000502:physiology*; D010710:Phosphates / Q000097:blood; D010920:Placenta / Q000187:drug effects / Q000378:metabolism*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D051381:Rats; D013965:Thyroidectomy
D002135:Calcium-Binding Proteins; D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010710:Phosphates; D002762:Cholecalciferol; D015650:24,25-Dihydroxyvitamin D 3; C013721:1,24,25-trihydroxyvitamin D3; D002117:Calcitriol; D002118:Calcium